Additional file 1 of Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Belotte, Jimmy; Felicetti, Brunella; Baines, Amanda J.; YoussefAgha, Ahmed; Rojas-Espaillat, Luis; Ortiz, Ana Godoy; Provencher, Diane; Vázquez, Raúl Márquez; Cortijo, Lucia González; Zeng, Xing

doi:10.6084/m9.figshare.25749987.v1

13063_2024_8142_MOESM1_ESM.pdf (163 kB)

Additional file 1 of Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

journal contribution

posted on 2024-05-04, 03:46 authored by Jimmy Belotte, Brunella Felicetti, Amanda J. Baines, Ahmed YoussefAgha, Luis Rojas-Espaillat, Ana Godoy Ortiz, Diane Provencher, Raúl Márquez Vázquez, Lucia González Cortijo, Xing Zeng

Additional file 1: Supplementary Table 1. Niraparib dose adjustments for hematologic toxicity.

Funding

GSK

History

Usage metrics

Keywords

Homologous recombination–deficient Interval debulking surgery Neoadjuvant chemotherapy Niraparib Ovarian cancer Overall response rate PARP inhibitor

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC